In November 2016, the FDA approved Sanofis Soliqua formulation (insulin glargine 100 units/mL and lixisenatide 33 mcg/mL). Soliqua became available in American pharmacies in January 2017. Society and culture
Cost
Following the US approval of Soliqua, Sanofi made a US$25 million milestone payment to Zealand. Zealand may receive additional payments up to US$110 million along with receiving royalties on global sales. Royalties paid to Zealand for Soliqua are based on a fixed low double-digit percentage of net sales.In January 2017, Sanofi announced that the wholesale acquisition cost (WAC) of a 3 ml pen of Soliqua is US$127. At the average dose used in clinical trials, this amounts to US$19.90 per day.According to Sanofis Half-Year Financial Report, the net sales of Soliqua reached €9 million in the first six months of availability in the United States. Brands
Insulin glargine/lixisenatide was called HOE901/AVE0010 during development and as of October 2017, had been marketed under the brand names iGlarLixi, Lantus/Lyxumia, LixiLan, and Soliqua. References
External links
"Insulin glargine mixture with lixisenatide". Drug Information Portal. U.S. National Library of Medicine.
Antibiotic treatment lowers the risk of embolic complications in people with infective endocarditis.In acute endocarditis, due to the fulminant inflammation, empirical antibiotic therapy is started immediately after the blood has been drawn for culture to clarify the bacterial organisms responsible for the infection. This usually includes vancomycin and ceftriaxone IV infusions until the infecting organism is identified and the susceptibility report with the minimum inhibitory concentration becomes available. Once this information is available, this allows the supervising healthcare professional to modify the antimicrobial therapy to target the specific infecting microorganism. The routine use of gentamicin to treat endocarditis has fallen out of favor due to the lack of evidence to support its use (except in infections caused by Enterococcus and nutritionally variant streptococci) and the high rate of complications. In cases of subacute endocarditis, where the persons hemodynamic status is usually stable, antibiotic treatment can be delayed until the causative microorganism can be identified.Viridans group streptococci and Streptococcus bovis are usually highly susceptible to penicillin and can be treated with penicillin or ceftriaxone. Relatively resistant strains of viridans group streptococci and Streptococcus bovis are treated with penicillin or ceftriaxone along with a shorter two-week course of an aminoglycoside during the initial phase of treatment.